PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 4, 20240 citations

Supplemental Figure S9 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

View Full Paper
JZJing ZhangDalian Medical UniversitySLSun Min LimYonsei UniversityMYMi Ra YuNational Taiwan University

Key Points

Key points are not available for this paper at this time.

Abstract

Supplemental Figure S9 shows the in vitro anti-tumor effect and tolerability of D3S-001 as monotherapy or in combination with D3S-002 on sotorasib-resistant models.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e59691b6db643587531527https://doi.org/10.1158/2159-8290.26935004.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplemental Figure S9 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024
  2. 2Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024
  3. 3Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024
  4. 4Supplemental Table S1 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024
  5. 5Supplemental Table S1 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities2024